About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ONC · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of…
NCT07934069 · Healthy Participants
BON-107, Placebo
ONC
BeOne Medicines
Phase 1Not yet recruiting100Oct 11, 2027Registry ↗
Nov 12, 2026An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Adva…
NCT07222267 · Breast Cancer, Advanced Solid Tumor
BG-75202, CDK4 Inhibitor
ONC
BeOne Medicines
Phase 1Recruiting186Sep 30, 2029Registry ↗
Nov 12, 2026A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic…
NCT06846671 · CLL, Chronic Lymphocytic Leukemia
Tacabrutideg, Bendamustine
ONC
BeOne Medicines
Phase 3Recruiting250May 15, 2028Registry ↗
Nov 10, 2026Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
NCT07836530 · Hepatocellular Carcinoma, Liver Cancer
BGB-B2033, Lenvatinib
ONC
BeOne Medicines
Phase 3Recruiting
was not yet recruiting
492Sep 21, 2029Registry ↗
Nov 4, 2026A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Pa…
NCT07856004 · Hepatic Impairment, Healthy Adult Participants
Tacabrutideg
ONC
BeOne Medicines
Phase 1Not yet recruiting24Jul 31, 2027Registry ↗
Nov 3, 2026Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular…
NCT07911683 · Hepatocellular Cancer, Liver Cancer
BGB-B2033
ONC
BeOne Medicines
Phase 2Not yet recruiting100Mar 31, 2028Registry ↗
Oct 29, 2026A Study of BON-C1393 in Adults With Advanced Solid Tumors
NCT07904845 · Solid Tumors, Advanced Solid Tumors
BON-C1393, Bevacizumab
ONC
BeOne Medicines
Phase 1Not yet recruiting90Feb 27, 2029Registry ↗
Oct 29, 2026A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Place…
NCT06742996 · Mantle Cell Lymphoma, B Cell Lymphoma
Sonrotoclax, Zanubrutinib
ONC
BeOne Medicines
Phase 3Recruiting300Aug 31, 2028Registry ↗
Oct 28, 2026A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473 · Advanced Solid Tumors
BG-C477, Tislelizumab
ONC
BeOne Medicines
Phase 1Recruiting310Jul 23, 2028Registry ↗
Oct 27, 2026A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patient…
NCT07896460 · Advanced Solid Tumor
BG-92505, Anti-Cancer Agent
ONC
BeOne Medicines
Phase 1Not yet recruiting137Aug 29, 2028Registry ↗
Oct 26, 2026An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
NCT07893535 · Solid Tumor, Advanced Solid Tumor
BON-106
ONC
BeOne Medicines
Phase 1Not yet recruiting96Dec 2030Registry ↗
Oct 26, 2026A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia a…
NCT07770698 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid L…
sonrotoclax, Azacitidine
ONC
BeOne Medicines
Phase 1/2Not yet recruiting30Apr 30, 2030Registry ↗
Oct 26, 2026A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients Wi…
NCT07733180 · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Eso…
Tislelizumab, Oxaliplatin
ONC
BeOne Medicines
Phase 2Recruiting30Feb 28, 2028Registry ↗
Oct 26, 2026BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+…
NCT07492641 · HR+/HER2- Breast Cancer
BGB-43395, Letrozole
ONC
BeOne Medicines
Phase 3Recruiting1,056Apr 2029Registry ↗
Oct 26, 2026A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in…
NCT06697184 · Chronic Lymphocytic Leukemia, CLL
Sonrotoclax, Zanubrutinib
ONC
BeOne Medicines
Phase 1/2Recruiting258Nov 30, 2029Registry ↗
Oct 26, 2026A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexam…
NCT04973605 · Relapsed/Refractory Multiple Myeloma
Sonrotoclax, Dexamethasone
ONC
BeOne Medicines
Phase 1/2Recruiting246Nov 2026Registry ↗
Oct 23, 2026A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
NCT07820891 · Healthy Adult Participants
BGB-43395, Midazolam
ONC
BeOne Medicines
Phase 1Recruiting24Nov 22, 2026Registry ↗
Oct 23, 2026A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents i…
NCT07746141 · RAS Mutation, Advanced Solid Tumor
BG-85738, Tislelizumab
ONC
BeOne Medicines
Phase 1Recruiting100Sep 30, 2028Registry ↗
Oct 23, 2026A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension o…
NCT07628881 · Healthy Volunteers
Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet
ONC
BeOne Medicines
Phase 1Completed12Sep 26, 2026Registry ↗
Oct 23, 2026A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax…
NCT06943872 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Sonrotoclax, Obinutuzumab
ONC
BeOne Medicines
Phase 3Recruiting630Sep 30, 2029Registry ↗
Oct 21, 2026A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in…
NCT07887646 · Diffuse Large B-Cell Lymphoma, B-cell Malignancies
BG-T0920
ONC
BeOne Medicines
Phase 1Not yet recruiting70Oct 31, 2029Registry ↗
Oct 21, 2026Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase…
NCT05294731 · B-cell Malignancy, Non-Hodgkin Lymphoma
Tacabrutideg
ONC
BeOne Medicines
Phase 1/2Recruiting146Jun 30, 2027Registry ↗
Oct 20, 2026A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participant…
NCT07855991 · Hepatic Impairment, Healthy Adult Participants
Sonrotoclax
ONC
BeOne Medicines
Phase 1Not yet recruiting12Feb 8, 2027Registry ↗
Oct 20, 2026An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents i…
NCT06589596 · Advanced Solid Tumor
BGB-58067, BG-89894
ONC
BeOne Medicines
Phase 1Recruiting695Aug 31, 2028Registry ↗
Oct 20, 2026A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Comb…
NCT05952037 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobuline…
Sonrotoclax, Zanubrutinib
ONC
BeOne Medicines
Phase 2Active, not recruiting114Sep 22, 2026Registry ↗
Oct 19, 2026A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in…
NCT07881211 · Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
BG-T0050
ONC
BeOne Medicines
Phase 1Not yet recruiting70Oct 31, 2029Registry ↗
Oct 16, 2026A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unre…
NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Sq…
Tislelizumab, Capecitabine
ONC
BeOne Medicines
Phase 2Recruiting30Dec 31, 2031Registry ↗
Oct 15, 2026A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients Wi…
NCT07652736 · Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small…
Tislelizumab
ONC
BeOne Medicines
—Recruiting440Nov 15, 2027Registry ↗
Oct 15, 2026BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Ad…
NCT06120283 · Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395, Fulvestrant
ONC
BeOne Medicines
Phase 1Recruiting433Dec 2029Registry ↗
Oct 15, 2026A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Rela…
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymp…
Zanubrutinib, Rituximab
ONC
BeOne Medicines
Phase 3Active, not recruiting799Jul 2028Registry ↗
Oct 14, 2026A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infus…
NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junctio…
Subcutaneous Tislelizumab, Intravenous Tislelizumab
ONC
BeOne Medicines
Phase 3Recruiting351Oct 30, 2027Registry ↗
Oct 14, 2026Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutu…
NCT06073821 · CLL
Sonrotoclax, Zanubrutinib
ONC
BeOne Medicines
Phase 3Active, not recruiting652Feb 2032Registry ↗
Oct 9, 2026A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazo…
NCT07590102 · Healthy Volunteers
BGB-58067, Phenytoin
ONC
BeOne Medicines
Phase 1Recruiting30Oct 31, 2026Registry ↗
Oct 5, 2026A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malig…
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma
Tacabrutideg
ONC
BeOne Medicines
Phase 1/2Recruiting689Mar 2027Registry ↗
Sep 30, 2026A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus…
NCT04002297 · Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
zanubrutinib, bendamustine
ONC
BeOne Medicines
Phase 3Active, not recruiting510Apr 27, 2026Registry ↗
Sep 28, 2026A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food…
NCT07712640 · Healthy Volunteers
BGB-58067 Tablet (F-01 Formulation), BGB-58067 Tablet (F-02…
ONC
BeOne Medicines
Phase 1Recruiting32Jul 1, 2027Registry ↗
Sep 28, 2026An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With My…
NCT07619287 · Myeloid Malignancy
BG-75202, Hypomethylation Agent (HMA)
ONC
BeOne Medicines
Phase 1Recruiting118Sep 30, 2028Registry ↗
Sep 28, 2026A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836 · Advanced Solid Tumor
BG-C0979, Tislelizumab
ONC
BeOne Medicines
Phase 1Recruiting84Apr 30, 2029Registry ↗
Sep 28, 2026A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetocla…
NCT07277231 · Chronic Lymphocytic Leukemia
Sonrotoclax, Zanubrutinib
ONC
BeOne Medicines
Phase 3Recruiting500Feb 2031Registry ↗
Sep 28, 2026A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349 · Advanced Solid Tumor
BG-75098, BGB-43395
ONC
BeOne Medicines
Phase 1Recruiting105Nov 1, 2028Registry ↗
Sep 28, 2026A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patien…
NCT07181681 · Solid Tumors, Advanced Solid Tumor
BG-C0902
ONC
BeOne Medicines
Phase 1Recruiting63Nov 1, 2027Registry ↗
Sep 28, 2026A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib i…
NCT06973187 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Tacabrutideg, Pirtobrutinib
ONC
BeOne Medicines
Phase 3Recruiting500Apr 17, 2028Registry ↗
Sep 28, 2026A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Adva…
NCT05981703 · Advanced Solid Tumor, Solid Tumor
BGB-26808, Tislelizumab
ONC
BeOne Medicines
Phase 1Recruiting337Feb 28, 2029Registry ↗
Sep 22, 2026Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cel…
NCT05471843 · Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL)
Sonrotoclax
ONC
BeOne Medicines
Phase 1/2Active, not recruiting125Jul 18, 2025Registry ↗
Sep 16, 2026A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizum…
NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatoc…
BGB-B2033, Tislelizumab
ONC
BeOne Medicines
Phase 1/2Recruiting630Mar 31, 2027Registry ↗
Sep 16, 2026Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapi…
NCT06233942 · Advanced Solid Tumor
BG-C9074, Tislelizumab
ONC
BeOne Medicines
Phase 1Recruiting308Sep 28, 2027Registry ↗
Sep 14, 2026BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epid…
NCT06756932 · Hormone-receptor-positive Breast Cancer, HER2-negative Brea…
BGB-21447, Fulvestrant
ONC
BeOne Medicines
Phase 1Recruiting120Jul 30, 2027Registry ↗
Sep 14, 2026A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
BGB-11417, Azacitidine
ONC
BeOne Medicines
Phase 1/2Recruiting260Aug 31, 2028Registry ↗
Sep 11, 2026A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Oth…
NCT06634589 · B-cell Malignancy, Relapsed Cancer
Tacabrutideg, Sonrotoclax
ONC
BeOne Medicines
Phase 1/2Recruiting80Dec 2, 2028Registry ↗
Sep 11, 2026Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanc…
NCT06598800 · Advanced Solid Tumor
Drug: BG-T187, Other Therapeutic Agents
ONC
BeOne Medicines
Phase 1Recruiting153Sep 30, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances